Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer

被引：0
|
作者：
Yin, Y. [1 ]
Duan, N. [1 ]
Hua, Y. [1 ]
机构：
[1] Nanjing Med Univ, Dept Oncol, Jiangsu Prov Hosp, Affiliated Hosp 1, Nanjing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.annonc.2023.09.1535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
32P
引用
收藏
页码：S196 / S197
页数：2
相关论文
共 50 条
  • [21] HER3 activation by MET contributes to trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, Kenji
    Macaulay, Valentine
    Kong, Anthony
    CANCER RESEARCH, 2014, 74 (19)
  • [22] NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer
    Yuan, Yuan
    Gao, Huanyao
    Zhuang, Yongxian
    Wei, Lixuan
    Yu, Jia
    Zhang, Zhe
    Zhang, Lili
    Wang, Liewei
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [23] Predictive factors of resistance to trastuzumab as neoadjuvant therapy in women with HER2-positive breast cancer
    Jinno, Hiromitsu
    Sato, Tomomi
    Takahashi, Maiko
    Hayashida, Tetsu
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)
  • [24] Albumin-bilirubin score predicts trastuzumab resistance in HER2-positive breast cancer
    Huang, Wen-Juan
    Yuan, Jia-Rui
    Zhang, Lei
    Wang, Wen
    Miao, Shi-Di
    Wang, Xin
    Wang, Rui-Tao
    CANCER BIOMARKERS, 2023, 38 (04) : 425 - 432
  • [25] Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
    Wang, Zhen-hao
    Zheng, Zhuo-qun
    Jia, Shi-cheng
    Liu, Shu-ni
    Xiao, Xiao-fen
    Chen, Guan-yuan
    Liang, Wei-quan
    Lu, Xiao-feng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
    Xing, Fei
    Gao, Hongli
    Chen, Guanglei
    Sun, Lisha
    Sun, Jiayi
    Qiao, Xinbo
    Xue, Jinqi
    Liu, Caigang
    MOLECULAR CANCER, 2023, 22 (01)
  • [27] Mechanisms behind trastuzumab resistance as neoadjuvant therapy in HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    CANCER RESEARCH, 2012, 72
  • [28] Association of Rac1 Expression with Trastuzumab Resistance In HER2-Positive Breast Cancer
    Varol, Umut
    Karaca, Burcak
    Patir, Pusem
    Sener, Alper
    Zekioglu, Osman
    Sanli, Ulus A.
    Uslu, Ruchan
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2013, 23 (04): : 219 - 226
  • [29] DNA methylation pattern to identify trastuzumab resistance in HER2-positive breast cancer models
    Palomeras, S.
    Diaz-Lagares, A.
    Setien, F.
    Ferreira, H. J.
    Hernandez, A.
    Vinas, G.
    Welm, A.
    Esteller, M.
    Puig, T.
    FEBS OPEN BIO, 2018, 8 : 314 - 314
  • [30] Nuclear HER3 localisation plays a role in trastuzumab resistance in HER2-positive breast cancer
    Hashimoto, K.
    Roxanis, I.
    Generali, D.
    Andreis, D.
    Strina, C.
    Cappelletti, M.
    Macaulay, V.
    Kong, A.
    CANCER RESEARCH, 2013, 73
12345